Stumbled upon this while researching the effects of vitamin K2 (MK-4) on blood coagulation. As you can see, the dose of vitamin K2 was not even that high - 20mg daily. ATRA was administered at 60mg daily. Keep in mind that the two toxic chemotherapeutic agents enocatibine and daunorubicin were already administered on their own and the patient relapsed. So, I think it is fair to say that the effect that amounts to a cure was due mostly/entirely to vitamin K2. Another shocking things is the speed with which vitamin K2 improved the condition - just one week!
I wonder how many people with leukemia out there (especially children) are getting poison as treatment when such a simple and cheap alternative exists.
http://www.ncbi.nlm.nih.gov/pubmed/9827941
"...Therefore we administered vitamin K2 (20mg/d) to our patient with APL together with enocitabine and daunorubicin. One week after the start of the new regimen promyelocytes disappeared from the peripheral blood (Fig. 1). Two months later bone marrow aspiration examination revealed complete cytogenic remission. In addition, PML/RARa fusion transcript and t(15;17) translocation disappeared."
I dug a little further and it seems that unlike vitamin K2, vitamin K1 has no curative effect against leukemia. So, another point for K2 and especially menatetrenone.
http://www.ncbi.nlm.nih.gov/pubmed/9177427
"...MK3, MK4, MK5 and GFO (at 10 microM) showed a potent apoptosis-inducing activity for all freshly isolated leukemia cells tested and for leukemia cell lines such as NB4, an acute promyelocytic leukemia (APL)-derived cell line and MDS92, a cell line derived from a patient with myelodysplastic syndrome, although there were some differences depending on the cells tested. In contrast, VK1 showed no effect on any of the leukemia cells. The combination of MK5 plus all-trans retinoic acid (ATRA) resulted in enhanced induction of apoptosis in both freshly isolated APL cells and NB4 cells as compared to each reagent alone. These data suggest the possibility of using VK2 and its derivatives for the treatment of myelogenous leukemias, including APL."
I wonder how many people with leukemia out there (especially children) are getting poison as treatment when such a simple and cheap alternative exists.
http://www.ncbi.nlm.nih.gov/pubmed/9827941
"...Therefore we administered vitamin K2 (20mg/d) to our patient with APL together with enocitabine and daunorubicin. One week after the start of the new regimen promyelocytes disappeared from the peripheral blood (Fig. 1). Two months later bone marrow aspiration examination revealed complete cytogenic remission. In addition, PML/RARa fusion transcript and t(15;17) translocation disappeared."
I dug a little further and it seems that unlike vitamin K2, vitamin K1 has no curative effect against leukemia. So, another point for K2 and especially menatetrenone.
http://www.ncbi.nlm.nih.gov/pubmed/9177427
"...MK3, MK4, MK5 and GFO (at 10 microM) showed a potent apoptosis-inducing activity for all freshly isolated leukemia cells tested and for leukemia cell lines such as NB4, an acute promyelocytic leukemia (APL)-derived cell line and MDS92, a cell line derived from a patient with myelodysplastic syndrome, although there were some differences depending on the cells tested. In contrast, VK1 showed no effect on any of the leukemia cells. The combination of MK5 plus all-trans retinoic acid (ATRA) resulted in enhanced induction of apoptosis in both freshly isolated APL cells and NB4 cells as compared to each reagent alone. These data suggest the possibility of using VK2 and its derivatives for the treatment of myelogenous leukemias, including APL."